Search

Smith & Nephew PLC

Geschlossen

1,210.5 0.29

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1170

Max

1211

Schlüsselkennzahlen

By Trading Economics

Einkommen

296M

Verkäufe

3B

KGV

Branchendurchschnitt

29.702

22.558

EPS

0.429

Dividendenrendite

3.04

Gewinnspanne

9.895

Angestellte

17,000

EBITDA

723M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+16.77% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.04%

4.45%

Nächstes Ergebnis

2. März 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

1.6B

11B

Vorheriger Eröffnungskurs

1210.21

Vorheriger Schlusskurs

1210.5

Smith & Nephew PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Jan. 2026, 19:05 UTC

Wichtige Markttreiber

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13. Jan. 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13. Jan. 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13. Jan. 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13. Jan. 2026, 23:13 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13. Jan. 2026, 23:10 UTC

Akquisitionen, Fusionen, Übernahmen

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13. Jan. 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13. Jan. 2026, 21:50 UTC

Akquisitionen, Fusionen, Übernahmen

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13. Jan. 2026, 21:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13. Jan. 2026, 21:20 UTC

Akquisitionen, Fusionen, Übernahmen

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13. Jan. 2026, 21:15 UTC

Akquisitionen, Fusionen, Übernahmen

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13. Jan. 2026, 21:08 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13. Jan. 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13. Jan. 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13. Jan. 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13. Jan. 2026, 19:08 UTC

Akquisitionen, Fusionen, Übernahmen

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13. Jan. 2026, 19:03 UTC

Ergebnisse

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13. Jan. 2026, 18:50 UTC

Ergebnisse

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13. Jan. 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13. Jan. 2026, 17:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Global Equities Roundup: Market Talk

13. Jan. 2026, 17:50 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13. Jan. 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13. Jan. 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13. Jan. 2026, 17:20 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Basic Materials Roundup: Market Talk

13. Jan. 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13. Jan. 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Smith & Nephew PLC Prognose

Kursziel

By TipRanks

16.77% Vorteil

12-Monats-Prognose

Durchschnitt 1,464.33 GBX  16.77%

Hoch 1,650 GBX

Tief 1,290 GBX

Basierend auf 9 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Smith & Nephew PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

9 ratings

5

Buy

4

Halten

0

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat